Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

• Status: Recruiting
• Trial end date: 2026-07-03
• Target enrollment: 0
• Participant gender: All

Summary

The proposed study is a prospective, single-center and open-ended study in patients over the age of 70 with treatment-naive diffuse large B-cell lymphoma (DLBCL). This study intends to explore a new treatment pattern using Pro-miniCHOP-like regimen and simultaneously evaluate its safety and efficacy for future clinical practice.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital of Soochow University
• Treatments: Pomalidomide; Rituximab

Criteria

Inclusion Criteria:

1. Histopathologically or Cytologically confirmed newly diagnosed untreated DLBCL;

2. There is at least one radiographically measurable lesion (i.e., ≥ 15mm in diameter);

3. Age ≥ 70 years;

4. Life expectancy >3 months;

5. Patients with proper organic function (alanine aminotransferase, bilirubin, creatinine < 3 times the upper limit of normal; cardiac ejection fraction ≥ 50%; SPO2>90% under non-oxygenated conditions).

6. Written informed consent obtained from the subject.

Exclusion Criteria:

1. Patients with severe liver and kidney dysfunction (alanine aminotransferase, bilirubin, creatinine > 3 times the upper limit of normal);

2. Patients with organic heart disease with clinical symptoms or cardiac dysfunction (NYHA grade ≥2);

3. Uncontrolled active infection;

4. Patients with central nervous system DLBCL;

5. A history of vascular embolism;

6. Co-existence of other tumors;

7. Systemic corticosteroid therapy is needed;

8. Any other psychological conditions that prevent patients from participating in the study or signing the informed consent form.